| Literature DB >> 34135173 |
Guan-Qun Ju1, Zhi-Jun Wang1, Jia-Zi Shi1, Zong-Qin Zhang1, Zhen-Jie Wu1, Lei Yin1, Bing Liu1, Lin-Hui Wang1, Dong-Liang Xu1,2.
Abstract
To evaluate outcomes between extraperitoneal robotic single-port radical prostatectomy (epR-spRP) and extraperitoneal robotic multiport radical prostatectomy (epR-mpRP) performed with the da Vinci Si Surgical System, comparison was performed between 30 single-port (SP group) and 26 multiport (MP group) cases. Comparisons included operative time, estimated blood loss (EBL), hospital stay, peritoneal violation, pain scores, scar satisfaction, continence, and erectile function. The median operation time and EBL were not different between the two groups. In the SP group, the median operation time of the first 10 patients was obviously longer than that of the latter 20 patients (P < 0.001). The median postoperative hospital stay in the SP group was shorter than that in the MP group (P < 0.001). The rate of peritoneal damage in the SP group was less than that in the MP group (P = 0.017). The pain score and overall need for pain medications in the SP group were lower than those in the MP group (P < 0.001 and P = 0.015, respectively). Patients in the SP group were more satisfied with their scars than those in the MP group 3 months postoperatively (P = 0.007). At 3 months, the cancer control, recovery of erectile function, and urinary continence rates were similar between the two groups. It is safe and feasible to perform epR-spRP using the da Vinci Si surgical system. Therefore, epR-spRP can be a treatment option for localized prostate cancer. Although epR-spRP still has a learning curve, it has advantages for postoperative pain and self-assessed cosmesis. In the absence of the single-port robotic surgery platform, we can still provide minimally invasive surgery for patients.Entities:
Keywords: extraperitoneal approach; minimally invasive surgery; prostate cancer; robotic radical prostatectomy; single-port
Mesh:
Year: 2021 PMID: 34135173 PMCID: PMC8577263 DOI: 10.4103/aja.aja_50_21
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Preoperative patient characteristics
|
|
|
|
|
|---|---|---|---|
| Age (year), median (IQR) | 64.5 (60.0–69.0) | 66.5 (61.0–69.3) | 0.542 |
| BMI (kg m−2), median (IQR) | 23.9 (21.7–25.3) | 23.7 (21.9–25.5) | 0.783 |
| Prior abdominal surgery, | 6 (20.0) | 5 (19.2) | 0.942 |
| PSA (ng ml−1), median (IQR) | 9.0 (7.9–9.8) | 9.4 (8.7–10.8) | 0.304 |
| cT stage, | 0.979 | ||
| cT1c | 16 (53.3) | 14 (53.8) | |
| cT2a | 10 (33.3) | 9 (34.6) | |
| cT2b | 4 (13.3) | 3 (11.5) | |
| Biopsy ISUP grade, | 0.799 | ||
| Grade group 1 | 21 (70.0) | 19 (73.1) | |
| Grade group 2 | 3 (10.0) | 3 (11.5) | |
| Grade group 3 | 6 (20.0) | 4 (15.4) | |
| D’Amico risk classification, | 0.757 | ||
| Low-risk | 22 (73.3) | 20 (76.9) | |
| Medium-risk | 8 (26.7) | 6 (23.1) | |
| IIEF-5 score, | 0.774 | ||
| >21 | 15 (50.0) | 12 (46.2) | |
| ≤21 | 15 (50.0) | 14 (53.8) |
IQR: interquartile range; BMI: body mass index; PSA: prostate-specific antigen; IIEF-5: International Index of Erectile Function; SP: single-port; MP: multiport; ISUP: International Society of Urological Pathology
Comparisons of intraoperative and postoperative data and complications between the single-port group and the multiport group
|
|
|
|
|
|---|---|---|---|
| Operative time (min), median (IQR) | 142.5 (129.5–180.0) | 134 (129.5–146) | 0.097 |
| EBL (ml), median (IQR) | 123.0 (115.0–160.0) | 120.0 (110.0–130.0) | 0.166 |
| Bladder catheterization (day), median (IQR) | 14 | 14 | |
| PSM, | 0 (0) | 0 (0) | |
| Hospital stay (day), median (IQR) | 4.5 (4.0–5.0) | 7.0 (6.0–8.0) | <0.001 |
| Transfusion rate, | 0 (0) | 0 (0) | |
| Peritoneum broken, | 0 (0) | 5 (19.2) | 0.017 |
| Lymphadenectomy, | 8 (26.7) | 6 (23.1) | 0.757 |
| Lymph node invasion, | 0 (0) | 0 (0) | |
| Nerve-sparing procedure, | 0.943 | ||
| Unilateral | 8 (26.7) | 6 (23.1) | |
| Bilateral | 18 (60.0) | 16 (61.5) | |
| None | 4 (13.3) | 4 (15.4) | |
| Complications, | 0.559 | ||
| Clavien I–II | 9 (30.0) | 6 (23.1) | |
| Clavien III–V | 0 (0) | 0 (0) | |
| ISUP grade after RP, | 0.827 | ||
| Grade group 1 | 12 (40.0) | 10 (38.5) | |
| Grade group 2 | 4 (13.3) | 3 (11.5) | |
| Grade group 3 | 9 (30.0) | 7 (26.9) | |
| Grade group 4 | 5 (16.7) | 6 (23.1) | |
| pT stage after RP, | 0.828 | ||
| T2a | 8 (26.7) | 9 (34.6) | |
| T2b | 12 (40.0) | 11 (42.3) | |
| T2c | 6 (20.0) | 3 (11.5) | |
| T3a | 4 (13.3) | 3 (11.5) | |
| Positive surgical margins, | 3 (10.0) | 2 (7.7) | 0.867 |
| Pain score, median (IQR) | |||
| Day of the operation | 6.0 (5.0–7.0) | 7.0 (6.8–8.0) | <0.001 |
| First postoperative day | 5.0 (4.8–6.0) | 7.0 (6.0–7.0) | <0.001 |
| Second postoperative day | 4.0 (3.0–4.3) | 4.0 (4.0–4.0) | 0.224 |
| Discharge day | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.874 |
| Need for any pain medication, | 11 (36.7) | 18 (69.2) | 0.015 |
| Need for opioids, | 2 (6.7) | 7 (26.9) | 0.04 |
| 3 months PSA <0.1 ng ml−1, | 29 (96.7) | 25 (96.2) | 0.536 |
| 3 months continence (0–1 pad per day), | 22 (73.3) | 20 (76.9) | 0.757 |
| 3 months erectile function recovery, | 10 (33.3) | 8 (30.8) | 0.838 |
| 3 months scar satisfaction, | 26 (86.7) | 14 (53.8) | 0.007 |
IQR: interquartile range; EBL: estimated blood loss; PSM: positive surgical margin; RP: radical prostatectomy; PSA: prostate-specific antigen; SP: single-port; MP: multiport; ISUP: International Society of Urological Pathology